Size: | Price | Quantity | |
---|---|---|---|
5 mg | $80.00 | ||
25 mg | $270.00 |
S07-2010 (1223194-71-5) is a pan-aldo-keto reductase 1C (AKR1C) inhibitor (IC50’s for AKR1C isoforms: 1C1 = 470 nM, 1C2 = 730 nM, 1C3 = 190 nM, 1C4 = 360 nM). Dysregulated AKR1C3 expression (and overexpression of all AKR1C isoforms in general) is related to resistance to radio- and chemotherapy in various tumor types and is associated with development of and poor prognosis in many cancers. S07-2010 displayed cytotoxicity to doxorubicin-resistant MCF-7 cells (IC50 = 127.5 µM) and cisplatin-resistant A549 cells (IC50 = 5.51 µM). Combination treatment of chemotherapeutic agents and S07-2010 showed synergistic effects in drug-resistant cell lines.
References/Citations:
C19H21N3O3S
98% by TLC NMR: (Conforms)
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
S07-2010 (1223194-71-5) is a pan-aldo-keto reductase 1C (AKR1C) inhibitor (IC50’s for AKR1C isoforms: 1C1 = 470 nM, 1C2 = 730 nM, 1C3 = 190 nM, 1C4 = 360 nM). Dysregulated AKR1C3 expression (and overexpression of all AKR1C isoforms in general) is related to resistance to radio- and chemotherapy in various tumor types and is associated with development of and poor prognosis in many cancers. S07-2010 displayed cytotoxicity to doxorubicin-resistant MCF-7 cells (IC50 = 127.5 µM) and cisplatin-resistant A549 cells (IC50 = 5.51 µM). Combination treatment of chemotherapeutic agents and S07-2010 showed synergistic effects in drug-resistant cell lines.
References/Citations:
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.